Efficacy News and Research

RSS
Syneron Medical to merge with Candela Corporation

Syneron Medical to merge with Candela Corporation

Sequoia Hospital completes 1000 atrial fibrillation ablation procedures

Sequoia Hospital completes 1000 atrial fibrillation ablation procedures

Patient enrollment completed in Phase II clinical trial of bavituximab

Patient enrollment completed in Phase II clinical trial of bavituximab

Maxim Health to launch its annual influenza vaccination program on October 1

Maxim Health to launch its annual influenza vaccination program on October 1

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

FDA approves Salix' METOZOLV ODT for treating diabetic gastroparesis

BioElectronics to file for FDA pre-marketing clearance of its ActiPatch Therapy product

BioElectronics to file for FDA pre-marketing clearance of its ActiPatch Therapy product

Amarillo Biosciences is midway in Phase 2 clinical study of interferon against H1N1

Amarillo Biosciences is midway in Phase 2 clinical study of interferon against H1N1

Rice researchers describe a new method to predict the efficacy of H1N1 vaccines

Rice researchers describe a new method to predict the efficacy of H1N1 vaccines

Meda launches EDLUAR in the U.S.

Meda launches EDLUAR in the U.S.

Increase in number of domestic H1N1 cases concerns China's Minister of Health

Increase in number of domestic H1N1 cases concerns China's Minister of Health

NIH awards Vaxart $2.8M grant to develop an orally-delivered H5N1 Avian influenza vaccine

NIH awards Vaxart $2.8M grant to develop an orally-delivered H5N1 Avian influenza vaccine

Can-Fite's Phase II clinical study of CF101 provides positive results

Can-Fite's Phase II clinical study of CF101 provides positive results

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

FDA approves ISTA's Bepreve for treating ocular itch

FDA approves ISTA's Bepreve for treating ocular itch

KRYSTEXXA development and treatment failure gout to be presented

KRYSTEXXA development and treatment failure gout to be presented

Valeant develops an acne drug with a low concentration of BPO combined with clindamycin

Valeant develops an acne drug with a low concentration of BPO combined with clindamycin

Opexa Therapeutics releases Phase IIb TERMS clinical study results

Opexa Therapeutics releases Phase IIb TERMS clinical study results

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

Pharma manufacturer's failure to disclose endangers Swine Flu vaccination program

Pharma manufacturer's failure to disclose endangers Swine Flu vaccination program

COPD patients to have better protection against pneumonia with new vaccine

COPD patients to have better protection against pneumonia with new vaccine

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.